Shigella Information Form
Healthy volunteers needed for Shigella vaccine study
Researchers at the Center for Vaccine Development and Global Health, University of Maryland, Baltimore, are conducting a vaccine and challenge study to evaluate the efficacy of an investigational Shigella vaccine. The study is open to adults aged 18 – 45 years and consists of up to 8 outpatient visits, including a screening session and 2 vaccinations, over 8 months (plus up to 2 months for screening). In Cohorts 1-3, participants may also have a 12-day inpatient stay. During the inpatient stay, participants will be “challenged” with live Shigella. The Shigella challenge involves exposure to the Shigella bacteria in order to evaluate whether or not the vaccine is effective in preventing Shigella infection.
The compensation goes up to $7350 if you participate in the inpatient challenge.
Shigella is a bacteria that can be ingested from contaminated food or water and causes a serious diarrheal infection, called dysentery. Shigella is one of the leading causes of diarrhea worldwide and is especially detrimental to children in developing countries. Globally, there are approximately 190 million diarrhea cases and an estimated 65,000 deaths due to Shigella each year. Shigella can be treated with oral and/or intravenous fluids and antibiotics; however, antibiotic resistance is increasing. There are currently no licensed vaccines against Shigella.